Thrafford
Get in touch

TiCoBi

One donor.
Up to fifteen doses.

Thrafford is developing India’s first scalable, off-the-shelf γδ T-cell therapy manufacturing platform, designed to eliminate measurable residual disease (MRD) before it causes AML relapse.

Explore TiCoBiView our patents

The platform

TiCoBi: Proprietary Time-Controlled Bioprocess

A proprietary, patent-filed, time-controlled bioprocess that expands a single healthy donor’s blood into up to 15 ready-to-use, off-the-shelf γδ T-cell doses — with no viral vectors, no gene editing and no patient-specific manufacturing.

  • No gene editing
  • No viral vectors
  • MHC-independent
  • Non-exhausted memory phenotype
  • Antigen-agnostic
  • Minimal GvHD risk

  1. Healthy donor

    Blood from a single healthy donor — not the patient.

  2. γδ T-cell isolation

    Gamma-delta T cells are isolated and purified ex vivo.

  3. Time-controlled expansion

    Temporally and volumetrically controlled expansion yields a non-exhausted memory phenotype.

  4. Up to 15 doses

    Off-the-shelf doses, ready when the clinician needs them.

Immune cells that find leukaemia without a map

Why γδ T cells

Immune-mediated elimination of leukaemia is most likely to work when disease burden is minimal — before overt relapse and an increasingly immunosuppressive microenvironment.

  • MHC-independent recognition

    γδ T cells recognise stress-induced ligands (MICA/B and ULBP family) on residual leukaemic cells, independently of classical HLA presentation.

  • Graft-versus-leukaemia, minimal GvHD

    Potent anti-leukaemic activity with minimal risk of graft-versus-host disease — the basis for allogeneic, off-the-shelf therapy.

  • Built for repeat dosing

    Suited to repeated administration during remission or in the peri-transplant setting, when disease burden is lowest.

Applications

One platform, many cell therapies

Our reagent-agnostic design reaches across oncology and autoimmune disease. Longer term, our AI and quantum computation initiative designs and optimises targets, algorithms and processes.

  • CAR-T therapies
  • NK & dendritic cell therapies
  • Autoimmune & infectious diseases
  • Solid tumours & advanced gene editing

Product portfolio

One platform, a growing pipeline

TiCoBi is antigen-agnostic. Beyond AML, the same process extends to glioblastoma and other solid tumours — and TiCoBi-generated γδ T cells can also supply partners’ CAR-T programmes.

ProgrammeIndicationModality
TLS-GD-001AM

Acute Myeloid Leukaemia

Lead programme
Allogeneic γδ T cellsTiCoBi
TLS-GD-001GB

Glioblastoma

Allogeneic γδ T cellsTiCoBi
TLS-GDC-001LL

Lymphoma & Leukaemia

γδ CD19 CAR-THealthy donor · one batch for 15 patients

In low- and middle-income countries, including India, accessibility remains a major challenge, which is why adopting PoCMAP can be a revolutionary intervention.

Point-of-care with PoCMAP

Shorter journeys from cell to patient

In conventional manufacturing, a patient’s cells are collected at the hospital, frozen and shipped to a distant facility, then frozen again and shipped back for infusion. Decentralising manufacturing to the hospital removes both journeys, reducing logistics and freeze–thaw cycles.

Point-of-care with PoCMAPA PoCMAP unit inside the treating hospital
Hospital 1
Cells collectedOn site, from the patient or donor
Manufactured on-site with PoCMAP 2
  • CAR-T
  • NK
  • Dendritic
Same platform, different cell systems 3
In-line QC 4Real-time sterility & quality checks
TreatedIn the same hospital

5Cell to patient without leaving the building: no inter-site shipping and fewer freeze–thaw cycles.

A modular platform built for hospitals

  1. 1

    Decentralised manufacturing

    Therapies are produced at the hospital, where the patient is treated.

  2. 2

    Parallel multi-batch processing

    Multiple batches run side by side to increase output.

  3. 3

    Platform-compatible

    Works with CAR-T, NK and dendritic cell systems.

  4. 4

    Built-in quality control

    Real-time sterility and quality control integration.

  5. 5

    Simpler logistics

    Reduced logistics and fewer freeze–thaw cycles.

Platform principles

Our three-pillar approach

Affordable. Scalable. Accessible.

Affordability

One batch — many patients

Allogeneic donor-derived therapies reduce manufacturing cost by enabling multi-patient batches.

Scalability

40× production capacity

Our modular platform delivers up to 40× capacity using parallel multi-batch processing systems.

Accessibility

Therapies closer to home

India’s first point-of-care CAR-T manufacturing system — enabling hospital-based therapy production.

Intellectual property

Protected by design

Our moat combines patent-filed manufacturing with trade-secret process logic — an integrated value chain that takes years of validation to rebuild.

  1. Patent filed

    Application no.

    2026••••2935

    Temporally and Volumetrically Controlled Process for Ex-vivo Expansion of V-Gamma-9V-Delta-2 T Cells

  2. Patent filed

    Application no.

    2025••••8309

    Point of Care Manufacturing Platform for Engineered Gamma Delta T cells

  3. Patent filed

    Application no.

    2025••••2865

    Point of Care Manufacturing and Processing Platform for Cell Therapy

See the team’s full patent record

Ongoing project

Conventional vs Quantum AI

We are mapping how human genes, proteins, metabolites, drugs and cells interact, drawing on the largest possible census of biomedical data resources and structuring it for quantum AI. The first goal is a working simulation of the immune system; every layer we add opens new questions, from cancer to autoimmunity and ageing.

Conventional AI

Scope
Models one layer of biology at a time, such as gene expression or protein binding, and joins the results afterwards.
Interactions
Trims the interactions it considers down to what classical hardware can compute.
Readiness
Mature, and in routine use across drug discovery today.

Quantum AI

Scope
Aims to hold several layers of human biology inside a single model.
Interactions
Explores interaction spaces that grow too quickly for exhaustive classical search.
Readiness
Still emerging. We are preparing the data now so it is ready when the hardware is.

Where the map will be used

  • Predicting adverse reactions

    Simulating how a patient’s immune system may respond to a cell therapy, including cytokine release syndrome and neurotoxicity, before the first dose.

  • Choosing targets

    Ranking the stress ligands, receptors and pathways worth pursuing in future γδ T-cell and CAR-T programmes.

  • Matching patients

    Identifying the patients most likely to respond, from the molecular profile of their disease.

  • Repurposing drugs

    Finding approved drugs that act on the same interaction networks as a disease, as candidates for new uses.

Partner with us on TiCoBi

Talk to us about clinical partnerships, our γδ T-cell programmes, or supplying γδ T cells for your CAR-T pipeline.

Start a conversationcontact@thrafford.com